"Non alcoholic fatty liver disease and eNOS dysfunction in humans"

Marcello Persico, Mario Masarone, Antonio Damato, Mariateresa Ambrosio, Alessandro Federico, Valerio Rosato, Tommaso Bucci, Albino Carrizzo, Carmine Vecchione

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: NAFLD is associated to Insulin Resistance (IR). IR is responsible for Endothelial Dysfunction (ED) through the impairment of eNOS function. Although eNOS derangement has been demonstrated in experimental models, no studies have directly shown that eNOS dysfunction is associated with NAFLD in humans. The aim of this study is to investigate eNOS function in NAFLD patients. Methods: Fifty-four NAFLD patients were consecutively enrolled. All patients underwent clinical and laboratory evaluation and liver biopsy. Patients were divided into two groups by the presence of NAFL or NASH. We measured vascular reactivity induced by patients' platelets on isolated mice aorta rings. Immunoblot assays for platelet-derived phosphorylated-eNOS (p-eNOS) and immunohistochemistry for hepatic p-eNOS have been performed to evaluate eNOS function in platelets and liver specimens. Flow-mediated-dilation (FMD) was also performed. Data were compared with healthy controls. Results: Twenty-one (38, 8%) patients had NAFL and 33 (61, 7%) NASH. No differences were found between groups and controls except for HOMA and insulin (p < 0.0001). Vascular reactivity demonstrated a reduced function induced from NAFLD platelets as compared with controls (p < 0.001), associated with an impaired p-eNOS in both platelets and liver (p < 0.001). NAFL showed a higher impairment of eNOS phosphorylation in comparison to NASH (p < 0.01). In contrast with what observed in vitro, the vascular response by FMD was worse in NASH as compared with NAFL. Conclusions: Our data showed, for the first time in humans, that NAFLD patients show a marked eNOS dysfunction, which may contribute to a higher CV risk. eNOS dysfunction observed in platelets and liver tissue didn't match with FMD.

Original languageEnglish
Article number35
JournalBMC Gastroenterology
Volume17
Issue number1
DOIs
Publication statusPublished - Mar 7 2017

Fingerprint

Blood Platelets
Liver
Blood Vessels
Dilatation
Insulin Resistance
Non-alcoholic Fatty Liver Disease
Aorta
Theoretical Models
Immunohistochemistry
Phosphorylation
Insulin
Biopsy
Control Groups

Keywords

  • Endothelial dysfunction
  • Insulin resistance
  • Metabolic syndrome
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

"Non alcoholic fatty liver disease and eNOS dysfunction in humans". / Persico, Marcello; Masarone, Mario; Damato, Antonio; Ambrosio, Mariateresa; Federico, Alessandro; Rosato, Valerio; Bucci, Tommaso; Carrizzo, Albino; Vecchione, Carmine.

In: BMC Gastroenterology, Vol. 17, No. 1, 35, 07.03.2017.

Research output: Contribution to journalArticle

Persico, Marcello ; Masarone, Mario ; Damato, Antonio ; Ambrosio, Mariateresa ; Federico, Alessandro ; Rosato, Valerio ; Bucci, Tommaso ; Carrizzo, Albino ; Vecchione, Carmine. / "Non alcoholic fatty liver disease and eNOS dysfunction in humans". In: BMC Gastroenterology. 2017 ; Vol. 17, No. 1.
@article{799b9d4a8ede4560aca5571b7d7d4d81,
title = "{"}Non alcoholic fatty liver disease and eNOS dysfunction in humans{"}",
abstract = "Background: NAFLD is associated to Insulin Resistance (IR). IR is responsible for Endothelial Dysfunction (ED) through the impairment of eNOS function. Although eNOS derangement has been demonstrated in experimental models, no studies have directly shown that eNOS dysfunction is associated with NAFLD in humans. The aim of this study is to investigate eNOS function in NAFLD patients. Methods: Fifty-four NAFLD patients were consecutively enrolled. All patients underwent clinical and laboratory evaluation and liver biopsy. Patients were divided into two groups by the presence of NAFL or NASH. We measured vascular reactivity induced by patients' platelets on isolated mice aorta rings. Immunoblot assays for platelet-derived phosphorylated-eNOS (p-eNOS) and immunohistochemistry for hepatic p-eNOS have been performed to evaluate eNOS function in platelets and liver specimens. Flow-mediated-dilation (FMD) was also performed. Data were compared with healthy controls. Results: Twenty-one (38, 8{\%}) patients had NAFL and 33 (61, 7{\%}) NASH. No differences were found between groups and controls except for HOMA and insulin (p < 0.0001). Vascular reactivity demonstrated a reduced function induced from NAFLD platelets as compared with controls (p < 0.001), associated with an impaired p-eNOS in both platelets and liver (p < 0.001). NAFL showed a higher impairment of eNOS phosphorylation in comparison to NASH (p < 0.01). In contrast with what observed in vitro, the vascular response by FMD was worse in NASH as compared with NAFL. Conclusions: Our data showed, for the first time in humans, that NAFLD patients show a marked eNOS dysfunction, which may contribute to a higher CV risk. eNOS dysfunction observed in platelets and liver tissue didn't match with FMD.",
keywords = "Endothelial dysfunction, Insulin resistance, Metabolic syndrome, Non-alcoholic fatty liver disease",
author = "Marcello Persico and Mario Masarone and Antonio Damato and Mariateresa Ambrosio and Alessandro Federico and Valerio Rosato and Tommaso Bucci and Albino Carrizzo and Carmine Vecchione",
year = "2017",
month = "3",
day = "7",
doi = "10.1186/s12876-017-0592-y",
language = "English",
volume = "17",
journal = "BMC Gastroenterology",
issn = "1471-230X",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - "Non alcoholic fatty liver disease and eNOS dysfunction in humans"

AU - Persico, Marcello

AU - Masarone, Mario

AU - Damato, Antonio

AU - Ambrosio, Mariateresa

AU - Federico, Alessandro

AU - Rosato, Valerio

AU - Bucci, Tommaso

AU - Carrizzo, Albino

AU - Vecchione, Carmine

PY - 2017/3/7

Y1 - 2017/3/7

N2 - Background: NAFLD is associated to Insulin Resistance (IR). IR is responsible for Endothelial Dysfunction (ED) through the impairment of eNOS function. Although eNOS derangement has been demonstrated in experimental models, no studies have directly shown that eNOS dysfunction is associated with NAFLD in humans. The aim of this study is to investigate eNOS function in NAFLD patients. Methods: Fifty-four NAFLD patients were consecutively enrolled. All patients underwent clinical and laboratory evaluation and liver biopsy. Patients were divided into two groups by the presence of NAFL or NASH. We measured vascular reactivity induced by patients' platelets on isolated mice aorta rings. Immunoblot assays for platelet-derived phosphorylated-eNOS (p-eNOS) and immunohistochemistry for hepatic p-eNOS have been performed to evaluate eNOS function in platelets and liver specimens. Flow-mediated-dilation (FMD) was also performed. Data were compared with healthy controls. Results: Twenty-one (38, 8%) patients had NAFL and 33 (61, 7%) NASH. No differences were found between groups and controls except for HOMA and insulin (p < 0.0001). Vascular reactivity demonstrated a reduced function induced from NAFLD platelets as compared with controls (p < 0.001), associated with an impaired p-eNOS in both platelets and liver (p < 0.001). NAFL showed a higher impairment of eNOS phosphorylation in comparison to NASH (p < 0.01). In contrast with what observed in vitro, the vascular response by FMD was worse in NASH as compared with NAFL. Conclusions: Our data showed, for the first time in humans, that NAFLD patients show a marked eNOS dysfunction, which may contribute to a higher CV risk. eNOS dysfunction observed in platelets and liver tissue didn't match with FMD.

AB - Background: NAFLD is associated to Insulin Resistance (IR). IR is responsible for Endothelial Dysfunction (ED) through the impairment of eNOS function. Although eNOS derangement has been demonstrated in experimental models, no studies have directly shown that eNOS dysfunction is associated with NAFLD in humans. The aim of this study is to investigate eNOS function in NAFLD patients. Methods: Fifty-four NAFLD patients were consecutively enrolled. All patients underwent clinical and laboratory evaluation and liver biopsy. Patients were divided into two groups by the presence of NAFL or NASH. We measured vascular reactivity induced by patients' platelets on isolated mice aorta rings. Immunoblot assays for platelet-derived phosphorylated-eNOS (p-eNOS) and immunohistochemistry for hepatic p-eNOS have been performed to evaluate eNOS function in platelets and liver specimens. Flow-mediated-dilation (FMD) was also performed. Data were compared with healthy controls. Results: Twenty-one (38, 8%) patients had NAFL and 33 (61, 7%) NASH. No differences were found between groups and controls except for HOMA and insulin (p < 0.0001). Vascular reactivity demonstrated a reduced function induced from NAFLD platelets as compared with controls (p < 0.001), associated with an impaired p-eNOS in both platelets and liver (p < 0.001). NAFL showed a higher impairment of eNOS phosphorylation in comparison to NASH (p < 0.01). In contrast with what observed in vitro, the vascular response by FMD was worse in NASH as compared with NAFL. Conclusions: Our data showed, for the first time in humans, that NAFLD patients show a marked eNOS dysfunction, which may contribute to a higher CV risk. eNOS dysfunction observed in platelets and liver tissue didn't match with FMD.

KW - Endothelial dysfunction

KW - Insulin resistance

KW - Metabolic syndrome

KW - Non-alcoholic fatty liver disease

UR - http://www.scopus.com/inward/record.url?scp=85014615399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014615399&partnerID=8YFLogxK

U2 - 10.1186/s12876-017-0592-y

DO - 10.1186/s12876-017-0592-y

M3 - Article

C2 - 28264657

AN - SCOPUS:85014615399

VL - 17

JO - BMC Gastroenterology

JF - BMC Gastroenterology

SN - 1471-230X

IS - 1

M1 - 35

ER -